医学
内科学
奥沙利铂
不利影响
养生
卡培他滨
胃肠病学
化疗
中性粒细胞减少症
淋巴结
癌症
外科
肿瘤科
结直肠癌
作者
J-W Shi,Yi Zhou,Shao-Dong Wu
出处
期刊:PubMed
日期:2023-11-01
卷期号:27 (21): 10472-10480
被引量:6
标识
DOI:10.26355/eurrev_202311_34324
摘要
The addition of adjuvant PD-1 inhibitor (Tislelizumab) to XELOX therapy showed a favorable impact on the one-year disease-free survival (DFS) rate when compared to adjuvant XELOX chemotherapy alone in patients with regional lymph node-positive disease after D2 radical gastrectomy. Moreover, patients were able to tolerate the accompanying adverse effects, which were deemed safe.
科研通智能强力驱动
Strongly Powered by AbleSci AI